Application of Inhalant Cannabidiol as a Novel and Non-Invasive Treatment of Drug Resistant Epilepsy
Abstract number :
2.473
Submission category :
7. Anti-seizure Medications / 7A. Animal Studies
Year :
2022
Submission ID :
2232966
Source :
www.aesnet.org
Presentation date :
12/4/2022 12:00:00 PM
Published date :
Nov 22, 2022, 05:29 AM
Authors :
Hesam Khodadadi, MD – Augusta University; Sahar Emami Naeini, MD – Augusta University; Evila Lopes Salles, PhD – Augusta University; Bidhan Bhandari, DDS – Augusta University; Navid Khorashahi, Student – Augusta University; Krishnan Dhandapani, PhD – Augusta University; Jack Yu, DMD, MD – Augusta University; Fernando Vale-Diaz, MD – Augusta University; Debra Moore-Hill, MD – Augusta University; Lei Phillip Wang, PhD – Augusta University; Babak Baban, PhD – Augusta University
This is a Late-Breaking abstract.
Rationale: Despite significant advances in patient outcomes, there are still significant therapeutic challenges in the treatment of epilepsy and its complications. While seizure frequency can be decreased and epilepsy modified in many, some patients remain medically resistant and are classified as having drug resistant epilepsy (DRE). Some patients may benefit from epilepsy surgery, yet others, who are poor surgical candidates remain without adequate seizure control. Therefore, continual drug and therapeutic exploration remains important for the treatment of epilepsy in patients with DRE._x000D_
_x000D_
Cannabidiol (CBD), a non-psychoactive cannabinoid, has shown beneficial effects in a variety of pathological conditions including epileptic seizures. In fact, a CBD based oil medication has been approved by FDA for the treatment of certain types of seizure disorders. Although CBD has been shown to be beneficial, current use of cannabidiol oil are often limited by the reported side effect of diarrhea (20%-30%). Continued work must be done to further elucidate the mechanistic link for CBD in the treatment of seizures. Also, based upon the side effect profile of the current formulation, exploration into new formulations of CBD based drugs with less potential side effects is warranted to control seizures more effectively, while minimizing unwanted side effects. In this study, we used for the first time, a new formulation of inhalant CBD to treat epileptic seizures in an experimental mouse model._x000D_
Methods: We used male 24 weeks old C57BL/6 mice (n=8). Mice were divided into two groups of 4 mice. The study group was pre-treated with inhalant CBD (8.5 mg) delivered using ApelinDx inhaler (Apelindx.com). After 30 minutes of CBD treatment, epileptic seizure was induced in all mice by intraperitoneal (i/p) injection of Kainic Acid (20 mg/kg). Racine Score scale was used to assess the severity of the experimental epileptic seizures._x000D_
Results: Epileptic seizure was induced in all mice; however, pretreatment with inhalant CBD was able to ameliorate the symptoms and curtailed the severity of the episode evaluated through Racine score scaling. Based on the scoring scale, CBD treated mice scored 2 or less. In comparison untreated mice (control group) scored between 4 and 5, (p < 0.05). _x000D_
Anti-seizure Medications